Previous studies indicated that activation mutations of the proto-oncogene KRAS and inactivation mutations of the tumour suppressor gene TP53, SMAD4 and CDKN2A were intimately linked to the occurrence, progression and dismal prognosis of pancreatic cancer (46, 47). This evidence concerns the gene KRAS and pancreatic neoplasm.